Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uromune
- Development stage
- Unknown
- Lead developer
- Inmunotek
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
**Uromune** is a sublingual, heat-inactivated polybacterial mucosal vaccine developed by Inmunotek and promoted in Spain by Q Pharma for prevention of recurrent bacterial urinary tract infections. The product contains equal proportions of inactivated whole-cell strains of *Escherichia coli*, *Klebsiella pneumoniae*, *Enterococcus faecalis*, and *Proteus vulgaris*. Sublingual exposure to these bacterial antigens promotes mucosal antigen presentation and systemic innate and adaptive immune responses, including trained innate immunity, intended to reduce recurrence of urinary tract infections.
- Brand names
- Uromune
- Other names
- Uromune AutovacunaUromune-MV140Uromune-MV-140Uromune-MV 140
Beyond the preview
Go deeper on Uromune.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Uromune.